Taken together, these data demonstrate that inhibition of KMT5C can induce DDR defects in NSCLC, that leading to activation of the STING‐IRF3 pathway, downstream type I IFN signaling and induce CCL5 expression. This evidence concerns the gene CCL5 and non-small cell lung carcinoma.